New diagnostic kits aim to revolutionize early screening of the disease, potentially allowing patients to receive treatments—such as monoclonal antibodies—sooner.

Affinity Technologies, Inc. ( ($BIAF) ) just unveiled an announcement. On November 5, 2025, bioAffinity Technologies announced significant ...

For the Fall Seminar Series, Emily McDermott, Jeffrey Lewis, Stephanie Williamson and Fiona L. Goggin will discuss ...

For managed care organizations and health systems, the recommendations strongly advocated highly selective use of NGS. Routine, nonselective NGS for all sarcoma patients is not justified. Instead, ...

Samuel Chen, CEO of AIxMed, also commented on the collaboration: "We recognize PathNet as a laboratory leader in urine cytology diagnostics. We are excited to provide an integrated and tested solution ...

Fujirebio's Lumipulse® G pTau217/β-Amyloid 1-42 Plasma Ratio test has the potential to shorten the Alzheimer's disease ...

A study from the University of Michigan Health Rogel Cancer Center and Department of Pathology shows that further testing in ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes ...

A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...

A chem 7 panel checks seven substances in the blood to show your general health. You might need to fast for at least eight hours before a chem 7 test. Abnormal chem 7 results could indicate an ...

Rules out Alzheimer's pathology in early stages to enhance diagnostic pathway efficiency Provides new opportunity to broaden access and improve referral quality Features as part of Roche's growing ...

Jeff Smith was dumbfounded when he received a colon cancer screening kit in the mail. The 68-year-old Minnesota man hadn't asked for the Cologuard test, and his doctor hadn't mentioned anything about ...